Drugs / FT596
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05934097 | Dec 2022 → May 2026 | diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma | Fate Therapeutics | Withdrawn | No outcome recorded |
| Phase 1 | NCT04555811 | Sep 2020 → Feb 2023 | high grade B-cell lymphoma | Masonic Cancer Center, University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT04245722 | Mar 2020 → Sep 2023 | B-cell chronic lymphocytic leukemia | Fate Therapeutics | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FT596 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04245722 ↗ |
| Modality | Cell therapy | “FT596 is an induced pluripotent stem-cell (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy” PMID 39798981 ↗ Jan 2025 |
| Route | Intravenous | “Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously” NCT05934097 ↗ |
| Target | CD19 | “a CD19 CAR” PMID 39798981 ↗ Jan 2025 |